Drug treatment reduces gout flares in clinical study

As reported in the journal Arthritis & Rheumatology, the drug febuxostat reduced gout flares in a double-blind, placebo-controlled study of 314 adults with early gout. Febuxostat treatment also reduced synovitis-or inflammation of the joint lining detected by MRI scanning -over a 2-year period compared with placebo.

Febuxostat treats high urate in the blood of patients with gout.

"Current clinical practice guidelines do not recommend routine use of urate-lowering therapy for people after the first gout flare. This study indicates that even for people who have had only 1 or 2 prior gout flares, urate-lowering therapy to reduce serum urate below 6mg/dL may have benefit in reducing future flares," said Dr. Nicola Dalbeth, lead author of the study.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
Points to consider when designing studies to improve outcome in people with inflammatory arthritis